NCT05270525
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
At risk: Primary completion moved at least 2 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 6 more changesShow less
- Eligibility criteria shortened, about 26 words
- Final enrollment: 70 participants (planned 56)
- Interventions modified
- Secondary endpoints: 13 to 22
- Study description shortened, about 274 words
- Study title expanded, about 6 words
Notable Eligibility criteria revised Show 6 more changesShow less
- Enrollment closed, study ongoing
- Primary completion pushed from Dec 2026 to Mar 1, 2027
- Study completion moved earlier from Jun 2027 to Mar 1, 2027
- Secondary endpoints: details revised at 1 of 13 entries
- Study description expanded, about 7 words
- Site details revised at 3 of 3 sites
- Notable Changed Sponsor changed: Verona Pharma plc to Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Notable Eligibility criteria expanded, about 9 wordsv6 Show 5 more changesShow less
- Primary endpoint revised
- Enrollment target: 50 to 56
- Study sites: 2 to 3
- Secondary endpoints: 7 to 13
- Study description shortened, about 9 words
- Notable Primary completion date: Dec 2024 to Dec 2026
- Study completion date: Dec 2024 to Jun 2027
Show 3 earlier versionsHide 3 earlier versions
- Minor Site details revised at 1 of 2 sitesv4
Notable Primary and study completion dates pushed to Dec 2024v3 Show 4 more changesShow less
- Eligibility criteria revised
- Enrollment target: 40 to 50
- Study sites: 1 to 2
- Study description shortened, about 32 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 1, 2022 to May 27, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (22)
Show 17 moreShow less
Arms and interventions
In treatment period 1 participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 1 participants will receive LABA/LAMA background therapy.
In treatment period 1 participants will receive placebo matching ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks followed by treatment period 2 during which participants will receive 3 mg ensifentrine twice daily administered via a standard jet nebulizer for 8 weeks. Throughout treatment sequence 2 participants will receive LABA/LAMA background therapy.
Drugs: Ensifentrine, Placebo, LABA/LAMA
Sites
3 sites in 1 country